Sex-specific Difference for Small Cell Lung Cancer from Immunotherapy Advancement

IF 8.7 3区医学 Q1 RESPIRATORY SYSTEM

Archivos De Bronconeumologia Pub Date : 2024-10-01 DOI:10.1016/j.arbres.2024.05.025

{"title":"Sex-specific Difference for Small Cell Lung Cancer from Immunotherapy Advancement","authors":"","doi":"10.1016/j.arbres.2024.05.025","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The treatment of lung cancer has witnessed significant progress, leading to improved survival rates among patients. It is important to assess the individual contributions of non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) to overall lung-cancer incidence and mortality trends based population, especially sex difference.</div></div><div><h3>Methods</h3><div>We analyzed lung cancer mortality based on subtype, gender, and calendar year. The Joinpoint software was used to identify any changes in incidence and trends in mortality.</div></div><div><h3>Results</h3><div>Incidence and incidence-based mortality declined from 2001 to 2019 both NSCLC and SCLC annually. The most significant decrease occurred between 2016 and 2019 with annual percent change of 5.71%. From 2012 to 2016, the incidence-based mortality of SCLC in women changed by 2.7% in tandem with incidence decreased 2.84%. Remarkably, the incidence-based mortality for women declined notably by 5.23% between 2016 and 2019, even as the incidence showed a less extent of decreasing (-2.59%). The survival rate for women was 15.2% in 2001, 19.3% in 2016, it had increased to 21.3% in 2018 but similar trends not in men. The survival curve showed the change in survival outcomes over time among men and women (median overall survival: 13 vs 23months) receiving immunotherapy for SCLC.</div></div><div><h3>Conclusion</h3><div>Population-level mortality from NSCLC and SCLC in the United States fell sharply from 2016 to 2019 as incidence deceased, and survival improved substantially. Our analysis suggests that approval for and use of immunotherapy may explain the mortality reduction observed during this period, with significant benefits especially for SCLC patient in women.</div></div>","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":null,"pages":null},"PeriodicalIF":8.7000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archivos De Bronconeumologia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0300289624001893","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The treatment of lung cancer has witnessed significant progress, leading to improved survival rates among patients. It is important to assess the individual contributions of non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) to overall lung-cancer incidence and mortality trends based population, especially sex difference.

Methods

We analyzed lung cancer mortality based on subtype, gender, and calendar year. The Joinpoint software was used to identify any changes in incidence and trends in mortality.

Results

Incidence and incidence-based mortality declined from 2001 to 2019 both NSCLC and SCLC annually. The most significant decrease occurred between 2016 and 2019 with annual percent change of 5.71%. From 2012 to 2016, the incidence-based mortality of SCLC in women changed by 2.7% in tandem with incidence decreased 2.84%. Remarkably, the incidence-based mortality for women declined notably by 5.23% between 2016 and 2019, even as the incidence showed a less extent of decreasing (-2.59%). The survival rate for women was 15.2% in 2001, 19.3% in 2016, it had increased to 21.3% in 2018 but similar trends not in men. The survival curve showed the change in survival outcomes over time among men and women (median overall survival: 13 vs 23months) receiving immunotherapy for SCLC.

Conclusion

Population-level mortality from NSCLC and SCLC in the United States fell sharply from 2016 to 2019 as incidence deceased, and survival improved substantially. Our analysis suggests that approval for and use of immunotherapy may explain the mortality reduction observed during this period, with significant benefits especially for SCLC patient in women.

Abstract Image

查看原文本刊更多论文

免疫疗法的发展对小细胞肺癌的性别差异。

背景：肺癌的治疗取得了重大进展，提高了患者的生存率。评估非小细胞肺癌（NSCLC）和小细胞肺癌（SCLC）对基于人群的整体肺癌发病率和死亡率趋势的贡献，尤其是性别差异，非常重要：我们根据亚型、性别和日历年分析了肺癌死亡率。结果：发病率和基于发病率的死亡率均有所下降：从 2001 年到 2019 年，NSCLC 和 SCLC 的发病率和基于发病率的死亡率逐年下降。最明显的下降发生在 2016 年至 2019 年，年变化百分比为 5.71%。从2012年到2016年，女性SCLC的发病死亡率下降了2.7%，与此同时，发病率也下降了2.84%。值得注意的是，在2016年至2019年期间，女性发病死亡率显著下降了5.23%，而发病率的下降幅度较小（-2.59%）。女性的存活率在 2001 年为 15.2%，2016 年为 19.3%，2018 年增至 21.3%，但男性的存活率却没有类似的趋势。生存曲线显示了接受免疫疗法治疗SCLC的男性和女性的生存结果随时间的变化（中位总生存期：13个月 vs 23个月）：2016年至2019年，随着发病率的下降，美国NSCLC和SCLC的人群死亡率急剧下降，生存率大幅提高。我们的分析表明，免疫疗法的批准和使用可能是在此期间观察到死亡率下降的原因，尤其是对女性SCLC患者有显著益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Archivos De Bronconeumologia Medicine-Pulmonary and Respiratory Medicine

CiteScore

3.50

自引率

17.50%

发文量

330

审稿时长

14 days

期刊介绍： Archivos de Bronconeumologia is a scientific journal that specializes in publishing prospective original research articles focusing on various aspects of respiratory diseases, including epidemiology, pathophysiology, clinical practice, surgery, and basic investigation. Additionally, the journal features other types of articles such as reviews, editorials, special articles of interest to the society and editorial board, scientific letters, letters to the editor, and clinical images. Published monthly, the journal comprises 12 regular issues along with occasional supplements containing articles from different sections. All manuscripts submitted to the journal undergo rigorous evaluation by the editors and are subjected to expert peer review. The editorial team, led by the Editor and/or an Associate Editor, manages the peer-review process. Archivos de Bronconeumologia is published monthly in English, facilitating broad dissemination of the latest research findings in the field.